QuidelOrtho Expands Immunoassay Portfolio via Lifotronic Partnership
Event summary
- QuidelOrtho signed a long-term supply agreement with Lifotronic Technology on February 16, 2026, to expand its global immunoassay portfolio.
- The deal adds multiple high-throughput and low-to-mid volume immunoassay analyzer platforms, with over 25 new assays not available on the VITROS system.
- Focus regions include Europe, Middle East, Africa, Latin America, India, China, Japan, and Asia-Pacific.
- The partnership aims to enhance QuidelOrtho's competitiveness in international tenders and serve a broader range of laboratory settings.
The big picture
This partnership allows QuidelOrtho to address menu gaps and enhance its competitive position in international markets where assay breadth and cost efficiency are critical. The deal reflects a broader trend in the diagnostics industry toward strategic collaborations to expand product offerings and geographic reach. Success will depend on regulatory approvals and effective market penetration in high-growth regions.
What we're watching
- Regulatory Approvals
- The pace at which the new products obtain required regulatory approvals in target markets will determine the deal's success.
- Market Penetration
- Whether QuidelOrtho can effectively compete for full-menu tenders in key international markets with the expanded portfolio.
- Operational Integration
- How seamlessly QuidelOrtho integrates Lifotronic's platforms and assays into its existing operations and customer offerings.
Related topics